Differences in Perioperative Hemodynamic Management for Pheochromocytoma and Paraganglioma

Alexander T. Reid, BA*; James H. Hammond, BS*; Adam C. Niemann, BS; Joshua D. Smith, BA; Stephanie A. DeBolle, BS; David T. Hughes, MD

* Authors contributed equally

ABSTRACT

Background
Pheochromocytomas (PCC) and paragangliomas (PG) are catecholamine-secreting tumors that can cause hemodynamic instability (HDI) in the perioperative period. Due to their similar pathology and clinical presentation, these tumors are often treated as a single disease. The hypothesis of this study is that patients with pheochromocytoma or paraganglioma will exhibit differing levels of perioperative HDI that may warrant disease-specific monitoring and/or treatment.

Methods
A retrospective analysis was performed on patients with pheochromocytoma or paraganglioma undergoing surgery at our institution from 2006–2015. Demographics, tumor characteristics, and perioperative variables were compared among the two tumor groups using Fisher’s Exact and Mann-Whitney-U tests with P values ≤ .05 considered significant. Simple linear regression was performed to identify predictors of intraoperative HDI in the pheochromocytoma group.

Results
There were no differences in patient demographics, tumor characteristics, or medication type/dosage required to achieve adequate α-blockade prior to surgery for the pheochromocytoma (n = 62) and paraganglioma (n = 15) groups. Paragangliomas were resected more frequently
with an open approach (P = .001) and had
greater estimated blood loss (P = .001). Para-
ganglioma patients experienced significantly
greater episodes of postoperative HDI (P = .003)
on overall comparison and on subgroup analysis
of the two tumor types after controlling for oper-
ative approach (P = .05). Significant predictors
of intraoperative HDI in the pheochromocytoma
group on simple regression included tumor size,
plasma normetanephrine/metanephrine levels,
and operative approach.

Conclusions
Preoperative hemodynamic variables and block-
ade requirements were similar between pheochro-
mocyтома and paraganglioma patients. However,
patients with paraganglioma were prone to more
complicated resections and HDI in the postoper-
ative period.

Introduction
Pheochromocytomas (PCC) and paraga-
gliomas (PG) are catecholamine-secreting
tumors of neuroendocrine chromaffin
cells with an estimated incidence of two-to-eight
per million.\(^1\) By convention, pheochromocytomas
are neoplasms of the adrenal medulla, whereas
paragangliomas arise from extra-adrenal gan-
glia of the autonomic nervous system.\(^2\) While
infrequently malignant, these tumors can cause
significant morbidity due to secretion of norepi-
nephrine and epinephrine. Patients often pres-
ent with symptoms of hypertension, palpitations,
headache, diaphoresis, and/or anxiety, and are
subject to complications such as stroke, arrhyth-
mias, and myocardial infarction.\(^5\) Surgical
resection is generally curative for these tumors
and is widely considered the gold standard of
treatment.\(^7\)

The surgeon physically touching these tumors
during surgery can cause them to secrete cate-
cholamines that subsequently result in hemo-
dynamic instability (HDI) hypertension (SBP >
140 mm Hg) or hypotension (SBP < 100 mm Hg),
requiring an intervention.\(^8\) Patients undergoing
surgical resection are also prone to labile blood
pressures in the postoperative setting.\(^9\) Careful
preoperative medical management is essential in
order to control hypertension and minimize HDI
in the perioperative period. Studies have shown
that pharmacologic agents such as the nonse-
lective α1-adrenergic blocker phenoxybenzamine,
selective α1-adrenergic blockers (eg prazosin,
doxazosin), β-adrenergic blockers, and calcium-
channel blockers can be titrated to achieve pre-
operative blood pressure control while minimizing
side effects.\(^6,10-12\)

Due to their similar pathology and clinical
presentation, pheochromocytomas and para-
gangliomas are often treated similarly; however,
recent studies have described significant differ-
ences between these tumors. Malignant para-
gangliomas behave more aggressively than their
malignant pheochromocytoma counterparts,
exhibiting more local and vascular invasion.\(^2\)
Additionally, patients with pheochromocytomas
may exhibit lower survival rates than those with
paragangliomas, possibly due to a more bio-
reactive hormone profile.\(^8\) Pheochromocytomas tend
to produce significant amounts of both norepi-
nephrine and epinephrine, while paragangliomas
only produce clinically significant levels of norepi-
nephrine and normetanephrine due to the lack of
phenylethanolamine N-methyltransferase, which
converts norepinephrine to epinephrine.\(^13\) Pre-
vious studies have shown that increased levels
of catecholamines, alpha-blockade type, hydra-
tion, tumor size, and procedure type may be
associated with perioperative HDI when resect-
ing pheochromocytomas.\(^6\) While the differences
in tumor features and clinical behavior between
pheochromocytomas and paragangliomas have
become more apparent in recent years, no study
has examined differences in perioperative HDI
between these tumors that may warrant disease-specific treatment or monitoring. Our hypothesis was that pheochromocytomas would have more instances of intraoperative HDI (given their ability to release both epinephrine and norepinephrine) compared to PGs that only release epinephrine despite similar preoperative pharmacologic blockade. Additionally, we hypothesize that larger tumor size and using an open procedure will result in greater blood loss, which will increase instances of intraoperative HDI. Given the ability of pheochromocytomas to secrete both epinephrine and norepinephrine, we hypothesize that these patients would require a longer duration of preoperative pharmacologic blockade, as well as higher doses of phenoxybenzamine to achieve the blockade.

Methods

Study Population

Following approval from the University of Michigan Institutional Review Board (IRB), a retrospective analysis of medical records was performed for patients undergoing resection of pheochromocytoma or paraganglioma at the University of Michigan between 2006 and 2015. All patients included in the study had a biochemically active (abnormal preoperative metanephrine and normetanephrine) paraganglioma or pheochromocytoma and underwent pharmacologic blockade prior to surgery under the direction of our institution’s surgeons. Patients with extra-abdominal paragangliomas (eg, carotid body) and biochemically inactive tumors (normal preoperative metanephrine and normetanephrine levels) were excluded from the analysis. The patient populations were not purposely matched for comparison between pheochromocytoma and paraganglioma groups. Five endocrine surgeons at our institution performed the majority of the pheochromocytoma and/or paraganglioma excisions in our study, and preference was given to the laparoscopic approach unless certain conditions (eg tumor location, invasion of adjacent abdominal structures) necessitated an open approach. The choice of medication employed for preoperative blockade depended on surgeon preference and patient factors. Phenoxybenzamine is generally preferred as the first-line blockade agent. When its use was limited by inadequate health insurance coverage or patient side effects (eg orthostatic hypotension, nasal congestion), calcium channel blockers were used instead.

Comparison Variables

Patients with pheochromocytoma and paraganglioma were compared on the basis of demographics (age and sex), tumor characteristics, and perioperative variables. Tumor characteristics compared among the pheochromocytoma and paraganglioma groups included tumor size, tumor location, presence of genetic mutations (such as succinate-dehydrogenase, Von Hippel-Lindau syndrome, etc), and baseline plasma normetanephrine levels and metanephrine levels at the time of initial presentation. Preoperative comparison variables included percentage of patients on α-blocking agents including phenoxybenzamine, duration of α-blockade, and percentage of patients on β-blockers and calcium-channel blockers. Intraoperative comparison variables included operative approach, operative time, estimated blood loss, fluid input, episodes of HDI, and vasoactive medications administered. Intraoperative HDI in our study was defined as the number of hypertensive (SBP > 140 mm Hg) or hypotensive (SBP < 100 mm Hg) episodes in which the anesthesiologist had to respond with a vasoactive substance. Postoperative HDI and duration of stay were compared among the two tumor groups. Postoperative HDI included episodes of hypertension (SBP > 140 mm Hg) or hypotension (SBP < 100 mm Hg) in which antihypertensive medications or fluid boluses were administered, respectively, in the first 48 hours after surgery.

A subgroup analysis was then performed in which the perioperative variables listed previously were compared between patients with
pheochromocytoma and paraganglioma. In this subgroup analysis, comparison groups were stratified on the basis of operative approach (open vs laparoscopic) to elucidate differences in perioperative parameters independent of the influence of operative approach.

**Statistical Analysis**

Statistical analysis was performed with SPSS and GraphPad Prism. In the comparison of perioperative variables among the two tumor groups, Fisher’s Exact Test was used for categorical variables, while the Mann-Whitney-U Test was used for continuous variables due to a nonparametric dataset. P values ≤ .05 were considered significant. Simple linear regression was used for analyzing significant predictors of intraoperative HDI within the pheochromocytoma group, with P ≤ .05 considered significant.

**Results**

Patient demographics, tumor characteristics, and preoperative management of patients are shown in Table 1. Sixty-two patients had a pheochromocytoma and 15 had a paraganglioma resection from 2006 to 2015. There were no significant differences in patient age or gender between the PCC and PG groups. Patients in the PG group demonstrated a higher rate of confirmed mutations (ie, succinate-dehydrogenase mutations) compared to patients in the PCC group (ie, Von Hippel-Lindau, Neurofibromatosis I, Multiple Endocrine Neoplasia Type II) by genetic testing (p = .003). Tumor sizes between the groups were similar, and all patients demonstrated elevated normetanephrine levels representing active hormone secretion from the tumor. As expected, PCC patients had higher plasma metanephrine levels compared to their PG counterparts (0.99 nM/L vs 0.20 nM/L, P = .002). Normal plasma metanephrine levels for our laboratory: ≤ 0.20 nM/L. Location of tumors in the PG group included para-aortic (8), paracaval (1), periaortic (2), renal vein (2), head of pancreas (1), and urinary bladder (1).

For control of preoperative blood pressures, α-blocking agents (phenoxybenzamine, doxazosin) were used in 63 patients (81.9%). A calcium-channel blocker (ie, Nicardipine) was used as the sole preoperative blood pressure control agent in 14 patients (18.1%). Both groups followed a similar preoperative course, with no significant differences in the number of patients on α-blockade, duration of blockade, final cumulative dose of phenoxybenzamine (mg/24 hr), or the number of patients on Ca²⁺ channel blockers or β-blockers (Table 1).

Operative parameters, intraoperative patient hemodynamics, and medications administered during surgical resection of PCC or PG are depicted in Table 2. An open approach to resection was performed more frequently in the PG group (80% vs 25.8% for PCC, P = .001). Similarly, the median operative time for PG resection was significantly longer than for PCC resection (238 minutes vs 153 minutes, P = .003). Patients in the PG group had greater blood loss (900 mL for PG vs 75 mL for PCC, P = .001) and required greater fluid resuscitation than their PCC counterparts (5.74 L for PG vs 4.21 L for PCC, P = .02). Patients in both groups experienced a similar number of episodes of HDI.

Postoperative outcomes are also depicted in Table 2. Patients in the PG group more frequently experienced HDI within the first 48 hours after surgery (53.3% PG patients vs 14.5% PCC patients, P = .003) and had longer median hospital stays (6 days for PG vs 3 days for PCC, P < .001) than patients with PCC.
TABLE 1. Patient Demographics, Tumor Characteristics, and Preoperative Management of Pheochromocytoma vs. Paraganglioma Groups

|                        | Pheochromocytoma (n = 62) | Paraganglioma (n = 15) | P Value |
|------------------------|---------------------------|------------------------|---------|
| Demographics           |                           |                        |         |
| Age (Age Range)        | 47 (13–87)                | 57 (20–72)             | .66     |
| Gender                 |                           |                        |         |
| Male                   | 27 (43.5%)                | 6 (40.0%)              | > .99   |
| Female                 | 35 (56.5%)                | 9 (60.0%)              | > .99   |
| Genetic Mutation Identified | 12 (19.4%)               | 9 (60.0%)              | .003    |
| Tumor Characteristics  |                           |                        |         |
| Tumor Size (cm)        | 4.10 (0.6–18.7)           | 5.30 (1.8–9.5)         | .44     |
| Plasma Normetanephrine levels (nM/L)<sup>a,b</sup> | 4.90 (1.1–111.0)          | 2.40 (1.4–36.6)        | .46     |
| Plasma Metanephrine levels (nM/L)<sup>a,b</sup> | 0.99 (0.20–25.0)          | 0.20 (0.20–0.23)       | .002    |
| PreOperative Management|                           |                        |         |
| Patients on α-Blockade | 50 (80.7%)                | 13 (86.7%)             | .73     |
| Duration of α-Blockade (days) | 36 (3–154)            | 29 (1–109)             | .26     |
| Cumulative Dose of Phenoxybenzamine (mg/24 hr) | 60 (12–240)              | 85 (0–120)             | .20     |
| Patients on Ca<sup>2+</sup>-Channel Blockers | 22 (35.5 %)             | 3 (20.0 %)             | 0.36    |
| Patients on β-Blockers | 41 (66.1 %)               | 9 (60.0 %)             | 0.77    |

Data are presented as median (range) or N (%)

<sup>SBP</sup> Systolic Blood Pressure, <sup,DBP</sup> Diastolic Blood Pressure

<sup>a</sup> Baseline plasma normetanephrine and metanephrine levels were not known for 6 PCC patients and 1 PG patient

<sup>b</sup> Reference range: normetanephrine levels ≤ 0.90 nM/L, metanephrine levels ≤ 0.20 nM/L

<sup>c</sup> Doxasozin was used in place of phenoxybenzamine in 3 PCC patients and 1 PG patient
**TABLE 2. Operative Parameters, Hemodynamic Instability, Medications Administered, and Postoperative Outcomes for Pheochromocytoma vs. Paraganglioma Groups**

| **Operative Parameters** | **Pheochromocytoma (n = 62)** | **Paraganglioma (n = 15)** | **P Value** |
|--------------------------|--------------------------------|----------------------------|-------------|
| Open Procedures          | 16 (25.8%)                     | 12 (80%)                   | .001        |
| Operative Time (min)     | 153 (68–425)                   | 238 (114–419)              | .003        |

**Intraoperative Hemodynamics**

|                        | **Pheochromocytoma** | **Paraganglioma** | **P Value** |
|------------------------|----------------------|-------------------|-------------|
| Estimated Blood Loss (mL) | 75.0 (2–6075)       | 900.0 (25–1300)   | .001        |
| IV Fluids Administered (L) | 4.21 (1.30–13.4)   | 5.74 (0.72–8.06)  | .02         |
| Episodes of HDI        | 3 (0–13)            | 2 (0–7)           | .99         |

**Medications Administered**

|                          | **Pheochromocytoma** | **Paraganglioma** | **P Value** |
|--------------------------|----------------------|-------------------|-------------|
| Magnesium Sulfate        | 30 (48.4%)           | 7 (46.7%)         | > .99       |
| β-Blockers               | 37 (59.7%)           | 6 (40%)           | .25         |
| Other Vasoactive Medicationsa | 47 (75.8%)     | 12 (80%)          | > .99       |

**Postoperative Outcomes**

|                          | **Pheochromocytoma** | **Paraganglioma** | **P Value** |
|--------------------------|----------------------|-------------------|-------------|
| Patients with HDIb       | 9 (14.5%)            | 8 (53.3%)         | .003        |
| Patients with Hypertension | 5 (8.1%)            | 6 (40%)           | .005        |
| Patients with Hypotension | 5 (8.1%)            | 4 (26.7%)         | .07         |
| Hospital Stay (days)     | 3 (2–42)             | 6 (1–21)          | < .001      |

Data are presented as median (range) or N (%)

*SBP* Systolic Blood Pressure, *DBP* Diastolic Blood Pressure

*a* Including Epinephrine, Norepinephrine, Vasopressin, Ephedrine, Phenylephrine

*b* Hypertension (SBP > 140 mm Hg) or Hypotension (SBP < 100 mm Hg requiring administration of anti-hypertensive meds or fluid boluses, respectively)

Given the higher rates of an open approach to resection for patients with paraganglioma, a subgroup analysis was performed, comparing perioperative hemodynamics among the two tumor groups controlled for operative approach (Table 3). Among patients undergoing an open approach to resection, those with pheochromocytoma experienced greater episodes of intraoperative HDI (4.5 episodes in PCC patients vs 2.0 episodes in PG patients, *P* = .04). Conversely, patients with PG undergoing a laparoscopic resection were statistically more prone to greater intraoperative blood loss (*P* = .03) and longer postoperative hospital stays (*P* = .006) and were more likely to have postoperative HDI (*P* = .05) in the first 48 hours after surgery, compared to patients with PCC having a laparoscopic resection.
TABLE 3. Significant Differences in PeriOperative Hemodynamics Among Pheochromocytoma and Paraganglioma Groups Stratified by Operative Approach

|                         | Open Approach (n = 28) | Laparoscopic Approach (n = 49) |
|-------------------------|------------------------|-------------------------------|
|                         | Pheochromocytoma n = 16 | Paraganglioma n = 12 | P Value | Pheochromocytoma n = 46 | Paraganglioma n = 3 | P Value |
| Episodes of Intraoperative HDI | 4.5 (0–13)             | 2.0 (0–7)                   | .04     | 2.0 (0–9)               | 4.0 (2–6)            | > .99   |
| Estimated Blood Loss (mL)    | 725 (30–6075)         | 763 (25–1300)              | .34     | 50 (0–800)              | 1150 (75–1250)       | .03     |
| Postoperative Hospital Stay (days) | 6.5 (4–10)         | 6.5 (2–42)                  | .83     | 2 (1–21)                | 5 (5–7)              | .006    |
| Patients w/ Postoperative Hypotension | 4 (25.0%)       | 6 (50.0%)                  | .24     | 5 (10.9%)               | 2 (66.7%)           | .05     |
| Patients w/ Postoperative HDI | 3 (18.8%)          | 2 (16.7%)                  | > .99   | 2 (4.3%)                | 2 (66.7%)           | .02     |

Data are presented as median (range) or N (%)

a 16 patients w/ pheochromocytoma and 12 patients w/ paraganglioma underwent open operations
b 46 patients w/ pheochromocytoma and 3 patients w/ paraganglioma underwent laparoscopic operations
c Hypertension (SBP > 140 mm Hg) or Hypotension (SBP < 100 mm Hg requiring administration of antihypertensive meds or fluid boluses, respectively)

Finally, to identify potential predictors of intraoperative HDI within the PCC group, simple linear regression was performed controlling for age, gender, tumor size, normetanephrine and metanephrine levels, pre-blockade SBP, duration of α-blockade, cumulative phenoxybenzamine dose, surgical approach, operative time, pre-induction SBP, and estimated blood loss. Due to the small sample size, simple regression models were not appropriately powered for the PG group and therefore were not performed.

**FIGURE 1.** Operative Approach and Tumor Size Predict HDI in Pheochromocytoma Resection

There were 62 total patients with pheochromocytoma. N for the tumor size < median and tumor size > median is thus 62/2 = 31 for each. N for lap approach is 46 and for open approach is 16
Significant individual predictors of intraoperative HDI in the PCC group are depicted in Table 4. To further delineate significant predictors of intraoperative HDI in the PCC group, the median number of episodes of intraoperative HDI was compared by dichotomizing the PCC group into those patients undergoing laparoscopic vs open surgical approach (Figure 1). As expected, patients with PCC undergoing an open approach experienced a greater number of episodes of intraoperative HDI than those undergoing a laparoscopic approach. The PCC group was again separated into two groups based on the median tumor size (4.1 cm) in this population (Figure 1). Patients with tumors larger than 4.1 cm (31 patients) were more prone to intraoperative HDI as compared with those patients with a tumor size less than 4.1 cm (31 patients).

**TABLE 4. Significant Individual Predictors of Intraoperative Hemodynamic Instability for PCC Group**

| Predictor Variable                  | N  | Estimated Coefficient | Standard Error (Estimated Coefficient) | 95% Confidence Interval | P Value |
|------------------------------------|----|-----------------------|----------------------------------------|-------------------------|---------|
| Age (years)                        | 62 | 0.044                 | 0.020                                  | 0.005–0.083             | .03     |
| Tumor Size (cm)                    | 62 | 0.403                 | 0.107                                  | 0.189–0.617             | < .001  |
| Plasma Normetanephrine Levels (nM/L)| 56 | 0.055                 | 0.013                                  | 0.030–0.080             | < .001  |
| Plasma Metanephrine Levels (nM/L)  | 56 | 0.174                 | 0.083                                  | 0.007–0.341             | .04     |
| Open Procedures                    | 16 | 2.758                 | 0.774                                  | 1.209–4.307             | .001    |
| Operative Time (min)               | 62 | 0.012                 | 0.005                                  | 0.003–0.021             | .01     |

N represents the number of patients with pheochromocytoma who had each variable entered into the regression analyses. Age, tumor size, number of procedures, and operative time were variables documented in the chart for each patient. For open procedures, only 16 patients had this type of procedure. Only 56/62 patients had preoperative plasma normetanephrine levels and preoperative metanephrine levels documented in MiChart.

**Discussion**

Our original hypothesis that patients with a pheochromocytoma would have more HDI was proven incorrect. It appeared that paraganglioma surgery was more often open and of longer duration than pheochromocytoma surgery (Table 2). This likely resulted in increased blood loss that led to more postoperative HDI in the paraganglioma group. However, the blood loss was likely not significant enough to result in intraoperative HDI but possibly only became apparent in the postoperative setting. Interestingly, when stratified by open approach, pheochromocytoma patients had more instances of intraoperative HDI than paraganglioma patients, which may, in fact, be due to differences in norepinephrine and epinephrine secretion of the tumor types (Table 3). Our hypothesis that larger tumor size and use of open approach would result in increased episodes of HDI intraoperatively was supported (Figure 1). Contrary to what we hypothesized, it appeared there were no differences between the two types of tumors with regard to preoperative pharmacologic blockade in terms of dosing, type of medication, or length of the blockade. Our intent with this study was to compare two distinct patient populations with either
of these tumor types on the basis of demographics, tumor characteristics, and perioperative variables to identify significant differences that may warrant disease-specific monitoring or treatment.

Pre-operative blockade of α-adrenergic receptors and stabilization of blood pressures is critical in preventing HDI due to catecholamine secretion from intraoperative tumor manipulation. Patients are generally considered to be appropriately blocked and thus optimized for resection of their tumors when hemodynamic parameters are normalized (ie, SBP 90–140 mm Hg, DBP 60–90 mm Hg, Pulse < 100 bpm). The broad range of duration of preoperative blockade in our patient population can be attributed to occasional difficulties with surgical scheduling, issues of patient adherence to medication, and longer times required to achieve adequate blockade. Our study showed that the preoperative courses of patients in the two cohorts were largely the same. Patients with PCC or PG exhibited similar baseline blood pressure readings, underwent a similar duration of preoperative α-blockade, and required similar cumulative phenoxybenzamine dosages (Table 1).

Important differences were found between the two tumor groups when analyzing the intraoperative variables, with our results suggesting that patients undergoing PG resection were prone to greater blood loss and longer operations than those patients undergoing PCC resection (Table 2). While an open approach to resection was more often necessary in the PG cohort, both tumor groups experienced a similar number of episodes of intraoperative HDI. The intraoperative use of magnesium sulfate at the discretion of the anesthesiologist and other vasoactive medications were similar among the two tumor groups.

Clinical practice guidelines currently recommend intensive postoperative monitoring for HDI in patients undergoing PCC or PG resection. However, postoperative morbidity and mortality in these patients remain uncommon. Recent research has attempted to identify tumor characteristics and patient factors that may better stratify patients into high- and low-risk groups for more personalized postoperative management. In our study, patients in the PG cohort more frequently had hypertension and/or hypotension requiring medical intervention in the first 48 hours after surgery, and they required significantly longer postoperative hospital stays than the patients in the PCC cohort (Table 2). These results may suggest differing postoperative HDI risk profiles in patients with PG vs PCC; perhaps more frequent SICU admission and more intensive postoperative monitoring is warranted for patients undergoing PG resection. However, in our study it is difficult to assert whether HDI in the PG group is due to pathologic properties of these tumors, or rather, due to the greater operative blood loss and more frequent open procedures.

In an attempt to address this question, we performed the subgroup analysis, comparing perioperative hemodynamic parameters among the pheochromocytoma and paraganglioma groups stratified by operative approach. Interestingly, patients undergoing an open resection of PCC were more prone to HDI than their counterparts undergoing open resection of PG. Similar to our initial, overall comparison between the two tumor groups, patients undergoing laparoscopic PG resection were statistically more likely to have greater intraoperative blood loss and to experience HDI in the postoperative setting. These results provide some support to the idea that inherent pathologic, anatomic, or clinical differences between pheochromocytomas and paragangliomas may confer differing risks of per-operative HDI. The difference in postoperative HDI between the two groups as identified in our study may provide support for a disease-specific approach to PCC and PG resection.

Our study has some limitations. Due to the rarity of PG and the low sample size of patients in our single-institution study, we are limited in our ability to identify predictors of intraoperative HDI in the PG cohort. Also, the utilization of vasoactive agents and magnesium sulfate to control HDI may differ significantly between institutions,
which may not allow for generalized comparisons. To further address these limitations, an expanded multicenter study involving larger patient groups is warranted. In general, our study was additionally limited by its retrospective nature; therefore, prospective studies comparing perioperative HDI in PCC and PG groups would be useful. Finally, there is a potential confounding bias in the PG cohort. The more challenging anatomic locations of PGs make a laparoscopic approach less feasible. This is likely a contributing factor to the differences in surgical approach and operative blood loss in our study.

Recent retrospective studies have identified the potential of clinically useful variables that predict intraoperative HDI in PCC resection, including cumulative phenoxybenzamine dose, use of intraoperative magnesium and vasopressin, and preoperative SBP. Our results were in agreement with these studies; we identified that larger tumor size and open surgical approach predict HDI in PCC resection. To strengthen our conclusions, a larger PCC cohort allowing for valid multivariable regression models would be useful. Additionally, a larger PG cohort would allow for similar regression models to identify predictors of intraoperative HDI in this group and to compare and contrast predictors across the two tumor groups.

Conclusion

Patients undergoing PCC or PG resection had similar preoperative pharmacologic blockade requirements and experienced a similar number of episodes of intraoperative HDI. However, patients in the PG cohort were prone to more complicated operations with greater blood loss, required more frequent open procedures, and were more likely to have HDI in the postoperative period. When controlling for operative approach, patients with PCC undergoing an open approach had greater intraoperative HDI than PG patients undergoing an open approach. Therefore, PG patients are more likely to undergo an open approach than PCC patients and require intensive monitoring. However, when PCC patients do require an open approach, they may need more intensive monitoring compared to PG patients who undergo open procedures. Conversely, patients with PG undergoing laparoscopic approach had greater intraoperative blood loss and postoperative HDI than patients with PCC undergoing a laparoscopic approach. Tumor size and operative approach appear to be predictive of intraoperative HDI in the PCC cohort.

References

1. Golden S, Robinson K, Saldanha I, Anton B, Ladenson PW. Clinical review: prevalence and incidence of endocrine and metabolic disorders in the United States: a comprehensive review. J Clin Endocrinol Metab. 2009;94(6):1853–1878.
2. Benn D, Gimenez-Roqueplo A, Reilly J, et al. Clinical presentation and penetrance of pheochromocytoma/paraganglioma syndromes. J Clin Endocrinol Metab. 2006;91(3):827–836.
3. Laird A, Gauger P, Doherty G, Miller B. Paraganglioma: not just an extra-adrenal pheochromocytoma. Langenbecks Arch Surg. 2012;397(2):247–253.
4. Renard J, Clerici T, Licker M, Triponez F. Pheochromocytoma and abdominal paraganglioma. J Visc Surg. 2011;148(6):409–416.
5. Ilias I, Pacak K. A clinical overview of pheochromocytomas/paragangliomas and carcinoid tumors. Nucl Med Biol. 2008;35(S1):27–34.
6. Kiernan C, Du L, Chen X, et al. Predictors of hemodynamic instability during surgery for pheochromocytoma. Ann Surg Oncol. 2014;21(12):3865–3871.
7. Goers T, Abdo M, Moley J, et al. Outcomes of resection of extra-adrenal pheochromocytomas/paragangliomas in the laparoscopic era: a comparison with adrenal pheochromocytoma. Surg Endosc. 2013;27(2):428–433.
8. Goffredo P, Sosa J, Roman S. Malignant pheochromocytoma and paraganglioma: a population level analysis of long-term survival over two decades. J Surg Oncol. 2013;107(6):659–664.
9. Chang R, Lang B, Wong K, Lo C. High pre-operative urinary norepinephrine is an independent determinant of peri-operative hemodynamic instability in unilateral pheochromocytoma/paraganglioma removal. World J Surg. 2014;38(9):2317–2323.
10. Weingarten T, Cata J, O’Hara J, et al. Comparison of two preoperative medical management strategies.
for laparoscopic resection of pheochromocytoma. *Urology*. 2010;76(2):6–11.

11. Agrawal R, Mishra S, Bhatia E, et al. Prospective study to compare perioperative hemodynamic alterations following preparation for pheochromocytoma surgery by phenoxybenzamine or prazosin. *World J Surg*. 2014;38(3):716–723.

12. Siddiqi H, Yang H, Laird A, et al. Utility of oral nicardipine and magnesium sulfate infusion during preparation and resection of pheochromocytomas. *Surgery*. 2012;152(6):1027–1036.

13. Grouzmann E, Tschopp O, Triponez F, et al. Catecholamine metabolism in paraganglioma and pheochromocytoma: similar tumors in different sites. *PLoS One*. 2015;10(5):e0125426. doi: 10.1371/journal.pone.0125426

14. Pacak K, Eisenhofer G, Ahlman H, et al. Pheochromocytoma: recommendations for clinical practice from the First International Symposium. *Nat Clin Pract Endocrinol Metab*. 2007;3(2):92–102.

15. Goldstein R, O’Neill J Jr, Holcomb G II, et al. Clinical experience over 48 years with pheochromocytoma. *Ann Surg*. 1999;229(6):755–764.

16. Lenders J, Duh Q, Eisenhofer G, et al. Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline. *J Clin Endocrinol Metab*. 2014;99(6):1915–1942.

17. Zeiger M, Thompson G, Duh Q-Y, et al. American Association of Clinical Endocrinologists and American Association of Endocrine Surgeons medical guidelines for the management of adrenal incidentalomas. *Endocr Pract*. 2009;15(5):1–20.

18. Lentschener C, Gaujoux S, Tesniere A, Doussset B. Point of controversy: perioperative care of patients undergoing pheochromocytoma removal-time for a reappraisal. *Eur J Endocrinol*. 2011;165(3):365–373.

19. Benay C, Tahiri M, Lee L, et al. Selective strategy for intensive monitoring after pheochromocytoma resection. *Surgery*. 2016;159(1):275–282.

20. Livingstone M, Duttchen K, Thompson J, et al. Hemodynamic stability during pheochromocytoma resection: lessons learned over the last two decades. *Ann Surg Oncol*. 2015;22(13):4175–4180.